Gianluca Musolino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gianluca Musolino has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Alena G. Thiele
Division for Paediatric Diabetology, University of Leipzig, Leipzig, Germany
1 shared publication- Birgit Rami-Merhar
Department of Pediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria
1 shared publication Carine de Beaufort
Department of Pediatric Diabetes and Endocrinology, Clinique Pédiatrique, Centre Hospitalier, Luxembourg City, Luxembourg
1 shared publication- Carlo L. Acerini
Department of Paediatrics, University of Cambridge, Cambridge, UK
1 shared publication - Charlotte K. Boughton
Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, U.K.
1 shared publication Craig Kollman
Jaeb Center for Health Research, Tampa, Florida
1 shared publication
Latest Publications
- Open Access
- 29 May 2019
- Published by Wiley in Pediatric Diabetes
- Vol. 20 (6) , 794-799
Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day‐and‐night hybrid closed‐loop use in very young children with type 1 diabetes
Objective To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day‐and‐night hybrid closed‐loop insulin delivery. Methods Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed‐loop experience survey following two 3‐week periods of unrestricted day‐and‐night hybrid closed‐loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed‐loop technology were explored. Results Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed‐loop. Ninety percent of the responders felt less worried about their child's glucose control using closed‐loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets. Conclusions Parents/caregivers of very young children reported important quality of life benefits associated with using closed‐loop, supporting adoption of this technology in this population.
- 29 May 2019
- Published by Wiley in Pediatric Diabetes
- Vol. 20 (6) , 794-799
Open AccessReduced burden of diabetes and improved quality of life: Experiences from unrestricted day‐and‐night hybrid closed‐loop use in very young children with type 1 diabetes
Objective To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day‐and‐night hybrid closed‐loop insulin delivery. Methods Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed‐loop experience survey following two 3‐week periods of unrestricted day‐and‐night hybrid closed‐loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed‐loop technology were explored. Results Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed‐loop. Ninety percent of the responders felt less worried about their child's glucose control using closed‐loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets. Conclusions Parents/caregivers of very young children reported important quality of life benefits associated with using closed‐loop, supporting adoption of this technology in this population.